New pill ZE50-0134 takes on Hard-to-Treat leukemia and lymphoma
NCT ID NCT06708897
First seen Jan 07, 2026 · Last updated Jun 20, 2026 · Updated 35 times
Summary
This early-stage study is testing a new oral drug called ZE50-0134 in 66 adults with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), or certain low-grade lymphomas that have come back or not responded to prior treatments. The main goal is to check the drug's safety and find the right dose, while also looking for signs that it can shrink or control the cancer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LYMPHOPLASMACYTIC LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Norton Cancer Institute, St. Matthews Campus
RECRUITINGLouisville, Kentucky, 40207, United States
-
The Ohio State University
RECRUITINGColumbus, Ohio, 43210, United States
-
University of Cincinnati
RECRUITINGCincinnati, Ohio, 45221, United States
-
University of North Carolina at Chapel Hill
RECRUITINGChapel Hill, North Carolina, 27599, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ZE50-0134 (oral capsule taken once daily)
What this could lead to
If this works, it could point toward a new treatment option for people with blood cancers that have stopped responding to other therapies.
What could go wrong
This is a very early Phase 1 trial with only 66 participants, so it is primarily testing safety. The drug may not work well or could have side effects, and it will take years before it might become available.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.